Axogen Inc Stock
Axogen Inc Stock
With only a change of -€0.030 (-0.080%) the Axogen Inc price is nearly unchanged from yesterday.
Pros and Cons of Axogen Inc in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Axogen Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Axogen Inc | -0.080% | 4.279% | -8.181% | 206.724% | 27.071% | 380.811% | 109.294% |
| Simulations Plus | 0.000% | 0.637% | 0.637% | -57.297% | 2.597% | -57.297% | -60.101% |
| MicroVision Inc | -1.680% | -19.604% | -20.631% | -78.515% | -71.738% | -93.800% | -98.199% |
| Fluidigm Corp. | -0.720% | -2.837% | 5.385% | -41.949% | -35.377% | -67.381% | -88.499% |
Comments
News
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February
